Introduction {#S0001}
============

Lung cancer, 85% of which are non-small cell lung cancer (NSCLC), remains the leading cause of cancer mortality globally.[@CIT0001] Upon diagnosis, the majority of NSCLC patients have locally advanced or metastatic disease. Conventional first-line chemotherapy in these patients confers a dismal median overall survival of 8--10 months and a 2-year survival rate of 11%.[@CIT0002],[@CIT0003]

The discovery of mutations of the *epidermal growth factor receptor* (*EGFR*) has completely revolutionized the management of patients with advanced NSCLC. *EGFR* (*HER 1*) is a transmembrane tyrosine kinase receptor belonging to the *HER* family.[@CIT0004] The binding of ligands consisting of transforming growth factor-α or epidermal growth factor to *EGFR* leads to auto-phosphorylation of key tyrosine residues.[@CIT0005] This activates downstream signalling involving and mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt which promotes cellular proliferation and survival. The presence of *EGFR* mutation results in constitutive activation of the MAPK and PI3K/Akt pathway independent of ligand binding, subsequently leading to the development and progression of NSCLC.

*EGFR*-tyrosine kinase inhibitors (*EGFR*-TKIs) including gefitinib, erlotinib, afatinib, dacomitinib and osimertinib bind to the ATP-binding sites of *EGFR*, thereby inhibiting the activation of the *EGFR*, MAPK and PI3K/Akt pathway.[@CIT0006],[@CIT0007] This results in reduced cellular proliferation and increased apoptosis. Several clinical trials have reported an impressive median progression-free survival (mPFS) of 9--13 months in NSCLC patients harbouring *EGFR*-TKI sensitising mutations treated with first-line gefitinib, erlotinib, or afatinib.[@CIT0005]

Despite the obvious efficacy of these *EGFR*-TKIs, the majority of these patients develop drug resistance after a median treatment period of one year mainly due to the acquisition of the *exon 20 T790M* resistant mutation. This study aims to determine the predictors of acquiring *T790M* mutation as a resistance mechanism among NSCLC patients who develop disease progression whilst taking first- or second-generation *EGFR*-TKI treatment.

Methodology {#S0002}
===========

Study Design and Patients {#S0002-S2001}
-------------------------

This is a retrospective observational study of NSCLC patients with sensitising *EGFR*-mutation who progressed while on first- or second-generation *EGFR*-TKI treatment with subsequent investigations to determine the mode of resistance at the University Malaya Medical Center (UMMC) from 1st January 2015 to 31st December 2017. All patients included had demonstrated an objective clinical benefit from the initial *EGFR*-TKI treatment as evidenced by either a complete response (CR), partial response (PR) or a minimum of six months of stable disease (SD) according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.[@CIT0008] They were investigated for resistance mechanisms as soon as the monitoring computed tomography (CT)-scan detected a PD according to RECIST version 1.1 criteria,[@CIT0009] without interruption of their *EGFR*-TKI treatment. Patients who had prior chemotherapy, inadequate tissue sample for resistance mechanism analysis, or incomplete medical records were excluded from this study. The study was conducted after receiving approval from the hospital medical ethics committee.

Procedure {#S0002-S2002}
---------

Patients who fulfilled the inclusion criteria were consecutively identified from the lung cancer registry of the Division of Respiratory Medicine, UMMC. Baseline demographic, clinical findings, treatment, pattern of PD, and investigation into resistance mechanisms were obtained from the electronic medical records.

At diagnosis, every patient underwent a baseline CT thorax, abdomen and pelvis (CT-TAP). CT-brain was only performed if there were neurological symptoms or signs. The initial tumor was staged according to the 7th edition of the American Joint Committee on Cancer system.[@CIT0010] All patients were tested for the presence of *EGFR* mutation in their pre-treatment biopsy specimens. Gefitinib or erlotinib was given in the first-line setting while afatinib was given either in the first-line setting or as a second-line treatment when patients failed to respond to gefitinib or erlotinib. Gefitinib and erlotinib are first-generation *EGFR*-TKI that bind reversibly to *EGFR*/ErbB1; while afatinib is second-generation *EGFR*-TKI that binds irreversibly to all the ErbB family (*EGFR*/ErbB1, *HER2*/ErbB2, ErbB3, and ErbB4).[@CIT0011],[@CIT0012] It was our standard practice to evaluate the tumor response by performing a repeat CT-TAP 4 weeks after initiation of *EGFR*-TKI and subsequently, once every three months. Tumor response was categorized according to RECIST version 1.1.[@CIT0009]

Before 1st December 2016, tissue re-biopsy was the first-line investigation at PD unless the patient refused, was unfit or the procedure was not technically feasible, in which case the patient would be offered liquid biopsy (detection of *T790M* mutation from a blood sample) as an alternative. Starting 1st December 2016, liquid biopsy was the first-line investigation while tissue re-biopsy was offered if liquid biopsy failed to detect acquired *T790M* mutation. We did not repeat tissue biopsy for those already tested negative for acquired *T790M* mutation in their re-biopsy tissue sample to prevent delay in initiation of second-line treatment. Identification of *c-MET* amplification by fluorescent in-situ hybridisation (FISH) was only done in seven patients who were tested negative for acquired *T790M* mutation and histological transformation during PD, as part of a clinical trial.[@CIT0013] Investigations for other resistance mechanisms were not available in Malaysia outside of clinical research during the period of this study.

Tissue Re-Biopsy {#S0002-S2003}
----------------

Tissue was obtained by either image-guided biopsy, endobronchial biopsy or excisional biopsy as clinically indicated. The histologic confirmation of lung cancer subtypes was based on tumor morphology on haematoxylin and eosin staining, complemented by immunohistochemical staining as needed to distinguish adenocarcinoma from squamous cell carcinoma. *T790M* mutation was detected by cobas^®^ *EGFR* Mutation Test v2 (Roche Molecular Systems, New Jersey, USA), an allele-specific real-time polymerase chain reaction (PCR) assay.

Liquid Biopsy {#S0002-S2004}
-------------

Detection of *T790M* mutation in circulating cell-free tumor DNA obtained in the plasma using the QIAamp^®^ Circulating Nucleic Acid kit (Qiagen, Hilden, Germany) was by the peptic nucleic acid-locked nucleic acid PCR (PNA-LNA PCR) clamp method (PANAGEN, Daejon, Korea) before 1st December 2016 and by droplet digital PCR (ddPCR) (Sanomics, Hong Kong, China) after that.

Statistical Analysis {#S0002-S2005}
--------------------

Categorical variables were expressed as percentages while continuous variables were expressed as mean ± standard deviation (SD) or median with range. Differences in clinical variables were examined between patients with acquired *T790M* mutation versus those without. Differences in categorical variables were compared using the Chi-Squared test or Fisher Exact test. Differences in continuous variables were compared using independent *t*-test or Mann--Whitney *U*-test. Multivariate analyses were performed using logistic regression. A two-sided p-value of \<0.05 was considered as statistically significant. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS for Windows version 23.0, SPSS Inc., Chicago, IL, USA).

Results {#S0003}
=======

Incidence of Acquired *T790M* Mutation and Other Resistance Mechanisms {#S0003-S2001}
----------------------------------------------------------------------

Of 122 patients with PD while on first- or second-generation *EGFR*-TKI, 87 patients who fulfilled the inclusion criteria were studied ([Figure 1](#F0001){ref-type="fig"}). At PD, acquired *T790M* mutation was found in 55 (63.2%) patients, two of whom (2.3%) also had concomitant small cell lung cancer (SCLC) transformation ([Figure 2](#F0002){ref-type="fig"}). Of the other patients, four (4.6%) had *c-MET* amplification, and one (1.1%) each had SCLC transformation and epithelial--mesenchymal transition (EMT), respectively. The resistance mechanism was unknown in 26 (29.9%) patients.Figure 1Algorithm of patient selection.**Abbreviations:** NSCLC, non-small cell lung cancer, *EGFR-TKI epidermal growth factor receptor-tyrosine* kinase inhibitor.Figure 2Incidence of acquired *T790M* mutation and other resistance mechanisms.**Abbreviations:** SCLC, small cell lung cancer; EMT, epithelial-mesenchymal transition.

Baseline Demographic, Clinical and Treatment History {#S0003-S2002}
----------------------------------------------------

The patients' baseline demographic and clinical characteristics, as well as treatment history, are shown in [Table 1](#T0001){ref-type="table"}. Of the initial sensitising *EGFR* mutations, 62.1% of patients had sensitizing *EGFR exon 19* deletion and the remaining patients had *EGFR exon 21 L858R* point mutation. For treatment in the first-line setting, 65.5% of patients received gefitinib, 16.1% received erlotinib and 18.4% received afatinib. Afatinib was also given in 12.6% of these patients as a second-line treatment before work-up for resistance mechanisms.Table 1Baseline Demographic, Clinical and Treatment Characteristics of Patients with Acquired *T790M* MutationCharacteristicsAll Patients (n = 87)Patients with T790M (n = 55)p value\***Age, year** Mean (± SD)61.7 ± 9.761.5 ± 10.10.693**Gender, No. (%)** Female5033 (66.0)0.532 Male3722 (59.5)**Ethnicity, No. (%)** Chinese6841 (60.3)0.294 Malay1210 (83.3) India74 (57.1)**Smoking history, No. (%)** Never smoker7044 (62.9)0.887 Former or current smoker1711 (64.7)**Baseline ECOG, No. (%)** 0--18052 (65.0)0.244 2--473 (42.9)**Tumour stage, No. (%)** IIIB85 (62.5)0.822 IVA2819 (67.9) IVB5131 (60.9)**Histology, No. (%)** Adenocarcinoma8655 (64.0)0.187 Large cell carcinoma10 (0)***EGFR* mutation subtype, No. (%)** *Exon 19 deletion*5438 (70.4)0.077 *Exon* 21 *L858R* point mutation3317 (51.5)**First-line *EGFR*-TKI treatment, No. (%)** Gefitinib5740 (70.2)0.134 Erlotinib146 (42.9) Afatinib169 (56.3)***EGFR*-TKI treatment before biopsy, No. (%)** 1st generation *EGFR*-TKI only6038 (63.3)0.683 2nd generation *EGFR*-TKI only169 (56.3) 1st followed by 2nd generation *EGFR*-TKI118 (72.7)**Best tumour response to *EGFR*-TKI, No. (%)0.008** Partial response72 (82.8)49 (68.1) Stable disease15 (17.2)6 (40.0)**Progression-free survival on *EGFR*-TKI, months** Median (95% CI)12.4 (10.9--13.9)12.6 (9.4--15.8)0.977**Duration from *EGFR*-TKI initiation to re-biopsy, months** Median (95% CI)17.3 (12.2--22.4)18.5 (13.1--23.9)0.321[^1][^2]

Acquired *T790M* mutation was found significantly more frequently in patients who achieved PR as the best response to the initial *EGFR*-TKI treatment compared to those who only had SD as the best response (68.1% versus 40.0%, p = 0.008). Patients with *EGFR exon 19* deletion were more likely to acquire *T790M* mutation at PD compared to those with *EGFR exon 21 L858R* point mutation (70.4% versus 51.5%, p = 0.077). The mPFS was slightly longer in patients who acquired *T790M* mutation compared to those who did not acquire *T790M* mutation (12.6 months versus 11.6 months, p = 0.977) ([Figure 3](#F0003){ref-type="fig"}). The median duration from *EGFR*-TKI treatment initiation to re-biopsy was also longer in patients with acquired *T790M* mutation compared to those who did not (18.5 months versus 16.2 months, p = 0.321)Figure 3Kaplan--Meier plot for progression-free survival of patients according to acquired *T790M* mutation status.

Pattern of Disease Progression {#S0003-S2003}
------------------------------

Upon PD, nearly half of the patients experienced enlargement of the lung primary, while 83.9% of the patients had new metastases ([Table 2](#T0002){ref-type="table"}). The lung (48.3%) was the commonest site of new metastases, followed by intrathoracic lymph nodes (24.1%), bones (20.7%) and the liver (18.4%). The brain (11.5%) and adrenal glands (2.3%) were uncommon sites of new metastases.Table 2Pattern of Disease Progression in Patients with Acquired *T790M* MutationCharacteristicsAll Patients (n = 87)Patients with T790M (n = 55)p value\***Number of progression sites, No. (%)** 14631 (67.4)0.260 22113 (61.9) 3178 (47.1) 433 (100)**Progression site, No. (%)** Enlarged lung primary1410 (71.4)0.242 New metastases4732 (68.1) Enlarged primary and new metastases2613 (50.0)**Enlarged lung primary, No. (%)** Yes4023 (57.5)0.308 No4732 (68.1)**New lung metastases, No. (%)0.048** Yes4231 (73.8) No4524 (53.3)**New symptomatic brain metastases, No. (%)0.021** Yes103 (30.0) No7752 (67.5)**New liver metastases, No. (%)** Yes1610 (62.5)0.947 No7145 (63.4)**New adrenal metastases, No. (%)** Yes22 (100.0)0.275 No8553 (62.4)**New intrathoracic lymph node metastases, No. (%)** Yes2110 (47.6)0.089 No6645 (68.2)**New bone metastases, No. (%)** Yes1813 (72.2)0.374 No6942 (60.9)[^3]

Acquired *T790M* mutation was significantly more frequent in patients who developed new lung metastases than those who did not (73.8% versus 53.3%, p = 0.048) and significantly less frequent in patients who had new symptomatic brain metastases than those who did not (30.0% versus 67.5%, p = 0.021). Patients who developed new intrathoracic lymph node metastases tended to be less likely to acquire *T790M* mutation than those who did not (47.6 versus 68.2%, p = 0.089).

Investigations for Resistance Mechanisms {#S0003-S2004}
----------------------------------------

Equal proportions of patients underwent liquid biopsy (40.2%) and tissue re-biopsy (40.2%) as the initial investigation to detect acquired *T790M* mutation, with a positive detection rate of 57.1% and 74.3%, respectively ([Table 3](#T0003){ref-type="table"}). Following an initial negative liquid biopsy, 19.6% of patients underwent a tissue re-biopsy, which detected *T790M* mutation in 52.9% of the cases.Table 3Investigations for Resistance Mechanisms in Patients with Acquired *EGFR* Exon 20 *T790M* MutationResistance Mechanism InvestigationAll Patients (n = 87)Patients with T790M (n = 55)p value\***Type of biopsy, No. (%)** Liquid biopsy3520 (57.1)0.205 Tissue re-biopsy3526 (74.3) Liquid followed by tissue re-biopsy179 (52.9)**Type of liquid biopsyAll patients (n = 52)Patients with *T790M* (n = 29)p value\*Liquid biopsy platform, No. (%)** PNA-LNA PCR2815 (53.6)0.730 ddPCR2414 (58.3)**Tissue re-biopsyAll patients (n = 52)Patients with *T790M* (n = 35)p value\*Site of re-biopsy, No. (%)** Lung primary2817 (60.7)0.323 Lung metastasis119 (81.8) Brain metastasis10 Liver metastasis108 (80.0) Lymph node metastasis21 (50.0)[^4][^5]

Among patients who underwent liquid biopsy, PNA-LNA PCR was performed in 46.2% of them with a *T790M* mutation detection rate of 58.3%, while ddPCR was performed in the remaining patients with a *T790M* mutation detection rate of 53.6%. The detection rate of acquired *T790M* mutation from tissue biopsy was 81.8% in biopsies of lung metastatic lesions, 80.0% in biopsies of liver metastatic lesions, 60.7% in lung primary tumor biopsies and 50.0% in intrathoracic lymph node biopsies. The investigation methods and sites of tissue biopsy did not have a significant effect on the *T790M* mutation detection rate.

Independent Predictors of Acquired *T790M* Mutation {#S0003-S2005}
---------------------------------------------------

In multivariate analysis, compared to SD, PR with *EGFR*-TKI treatment was associated with a significantly higher rate of acquiring *T790M* mutation at PD (OR: 4.1, 95% CI: 1.24--13.50, p = 0.021) ([Table 4](#T0004){ref-type="table"}); while the development of new symptomatic brain metastases or new intrathoracic lymph node metastases at PD was associated with significantly lower rates of acquired *T790M* mutation (OR: 0.2, 95% CI: 0.04--0.88, p = 0.034 and OR: 0.3, 95% CI: 0.11--0.94, p = 0.038, respectively). Patients with sensitizing *EGFR exon 19* deletion were more likely to acquire *T790M* mutation compared to those with sensitizing *EGFR exon 21 L858R* point mutation (OR: 2.3, 95% CI: 0.84--6.25, p = 0.104). Otherwise, the type of first-line *EGFR*-TKI received and having new lung metastases during PD did not have a significant effect on the *T790M* mutation rate.Table 4Multivariate Analysis of Predictors of Acquiring *T790M* MutationCharacteristicsAll Patients (n = 87)Patients with T790M (n = 55)Multivariate Analysis, OR (95% CI), p value***EGFR* mutation subtypes, No. (%)** *Exon 19* deletion5438 (70.4)2.3 (0.84--6.25), 0.104 *Exon 21 L858R* point mutation^\#^3317 (51.5)**First-line *EGFR*-TKI, No. (%)** Gefitinib5740 (70.2)1.6 (0.41--6.38), 0.491 Erlotinib146 (42.9)0.5 (0.09--2.70), 0.424 Afatinib^\#^169 (56.3)**Best tumour response, No (%)**4.1 (1.24--13.50),**0.021** Partial response7249 (68.1) Stable disease^\#^156 (40.0)**New lung metastases, No. (%)** Yes4231 (73.8)1.6 (0.54--4.55), 0.404 No^\#^4524 (53.3)**New symptomatic brain metastases, No. (%)**0.2 (0.04--0.88),**0.034** Yes103 (30.0) No^\#^7752 (67.5)**New intrathoracic lymph nodes metastases, No. (%)**0.3 (0.11--0.94),**0.038** Yes2110 (47.6) No^\#^6645 (68.2)[^6][^7]

Clinical and Treatment Characteristics of Patients Without PD {#S0003-S2006}
-------------------------------------------------------------

At the time of data cut-off, 29 patients continued to receive first- or second-generation *EGFR*-TKI without PD. 88.4% of these patients had *EGFR exon 19* deletion and the remaining patients had *EGFR exon 21 L858R* point mutation as the original sensitizing mutation. 48.2% of patients received gefitinib, 27.6% received erlotinib and 24.2% received afatinib as the choice of *EGFR-*TKI selected in the first-line setting. 82.7% of patients had PR and the remaining had SD as the best tumour response. The median follow-up period for this group of patients was 17.1 months (95% CI: 6.38--27.82).

Osimertinib After Failure of First- or Second-Generation *EGFR*-TKI {#S0003-S2007}
-------------------------------------------------------------------

Nineteen (34.5%) patients with acquired *T790M* mutation received osimertinib soon after first- or second-generation *EGFR*-TKI failure. The care of three of these patients were transferred to another center and further details about their response to osimertinib were not available. The second mPFS for the remaining 16 patients treated with osimertinib was 8.0 months (95% CI: 1.75--14.25).

Discussion {#S0004}
==========

The present study identified acquired *T790M* mutation as the commonest resistance mechanism causing treatment failure to first- or second-generation *EGFR*-TKI in Malaysian patients with sensitising *EGFR*-mutant NSCLC. Having the best tumour response of PR while on first-line *EGFR-*TKI was the only significant independent predictor of acquiring *T790M* mutation causing PD. Acquired *T790M* mutation was more common in patients with tumors harbouring *exon 19* deletion than those with *exon 21 L858R* point mutation as their original sensitizing mutation. On the other hand, the presence of new symptomatic brain metastases or intrathoracic lymph node metastases upon PD was significant independent predictors against acquiring *T790M* mutation. The yield of detecting *T790M* mutation from either tissue or liquid biopsy in the present study was high. Performing reflex tissue re-biopsy after the failure of liquid biopsy to detect *T790M* mutation could detect this resistance mutation in half of the cases.

The incidence of acquired *T790M* mutation in the present study corresponds to that of 45.1% to 62.0% reported in the literature.[@CIT0014]--[@CIT0022] Several studies have highlighted a longer mPFS with *EGFR*-TKI treatment as the most important independent predictor of acquired *T790M* mutation.[@CIT0018],[@CIT0019],[@CIT0021]-[@CIT0024] Even though the mPFS of our patients who acquired *T790M* mutation was slightly longer than the mPFS of those who did not acquire *T790M* mutation, the difference was not statistically significant because of the small number of patients. The exclusion of a number of prolonged *EGFR*-TKI responders who had not experienced PD in the present study could be a confounding factor because previous studies suggested these patients are more likely to acquire *T790M* mutation at PD.[@CIT0018],[@CIT0019],[@CIT0021]-[@CIT0023]

A few studies have shown that initial *exon 19* deletion mutation is another predictor of acquiring *T790M* mutation as a resistance mechanism.[@CIT0019]--[@CIT0021],[@CIT0025] The present study too showed a trend favoring acquired *T790M* mutation among patients with initial sensitizing *EGFR exon 19* deletion compared to those with *EGFR exon 21 L858R* point mutation. The lack of statistical significance could be attributed to the small number of patients in our study. Matsuo et al reported a significant association of better tumour response to *EGFR*-TKI with acquired *T790M* mutation (objective response rate: 84.7% versus 60.0%, p = 0.001) which is also shown by the present study.[@CIT0019] Oxnard et al and Hata et al, respectively, reported extra-thoracic disease progression (p = 0.014) and new brain metastases (p = 0.042) as features against acquiring *T790M* mutation as a resistance mechanism.[@CIT0015],[@CIT0023] Our finding is in agreement with the latter observation. A recent study by Del Re et al reported a higher incidence of *T790M* mutation detected by plasma biopsy at PD among patients receiving first-line gefitinib or erlotinib compared to afatinib.[@CIT0026] Otherwise, the present study and other studies consistently observe that gender, smoking status, proportion of stage IV disease and the site of re-biopsy do not have a significant effect on the frequency of acquired *T790M* mutation.[@CIT0021],[@CIT0023],[@CIT0027],[@CIT0028]

The substitution of methionine by threonine at the gatekeeper residue in position 790 of the *EGFR* kinase domain leads to *T790M* mutation which confers resistance to first- or second-generation *EGFR*-TKI by steric hindrance to TKI, increased ATP-binding affinity and increased in auto-phosphorylation levels.[@CIT0029]--[@CIT0031] The emergence of *T790M* mutation during *EGFR*-TKI treatment could be by selection or by acquisition.[@CIT0032]--[@CIT0034] In the selection hypothesis, a small proportion of *T790M* resistant clone is already present even before *EGFR*-TKI therapy. This *T790M* clone proliferates when the sensitive clones are successfully eradicated by *EGFR*-TKI therapy. This hypothesis is supported by the discovery of de novo *T790M* mutation in 31.5--38.0% of patients with sensitising *EGFR*-mutant NSCLC prior to treatment.[@CIT0035]--[@CIT0037] On the other hand, the acquisition hypothesis suggests that the tumor cells develop novel genetic or epigenetic defects as a consequence of prolonged *EGFR*-TKI treatment.[@CIT0038]--[@CIT0040] In the light of these two hypotheses, the higher incidence of acquired *T790M* mutation among patients who achieve PR with *EGFR*-TKI can be explained by the selection model while the higher incidence of acquired *T790M* mutation among patients with longer mPFS and longer duration on *EGFR*-TKI treatment before biopsy can be explained by the acquisition model.

Compared to patients with *exon 21 L858R* point mutation, better tumour response and longer mPFS among patients with *exon 19* deletion may reflect the higher incidence of acquired *T790M* mutation in patients with the latter mutation.[@CIT0041] Secondary *T790M* mutation is less likely in patients who experience new brain metastases because first- or second-generation *EGFR*-TKI do not cross the blood-brain barrier well to promote *T790M* mutation resistance by selection or acquisition mechanisms.

The findings of our study further complement the result of existing literature. While ethnicity, smoking status and histologic subtypes of lung cancer are associated with initial *EGFR* mutation, the present study and other studies show that initial *EGFR* mutation subtypes, tumor response to *EGFR*-TKI treatment and sites of PD are predictors of acquired *T790M* mutation.[@CIT0018],[@CIT0019],[@CIT0021]-[@CIT0023],[@CIT0025],[@CIT0042],[@CIT0043] The initial *EGFR* mutation subtypes and best tumor response while on *EGFR*-TKI treatment are the clinically more relevant predictors of acquired *T790M* mutation compared to PFS and sites of PD. This is because these information enable the treating clinicians to predict the likelihood of their patients developing *T790M* mutation before the actual PD, and therefore allows early prognostication and management planning. Patients with tumors harbouring *exon 19* deletion and patients who achieve PR as the best tumor response while on *EGFR*-TKI shall have a better overall survival because they are more likely to acquire *T790M* mutation as a cause of PD. This is supported by several studies that report a significantly longer post-progression survival in patients with acquired *T790M* mutation compared to those without.[@CIT0015],[@CIT0020],[@CIT0023]

The importance of planning tissue sampling carefully when patients fail *EGFR*-TKI is also highlighted in the current study. First, acquired *T790M* mutation could be detected in tissue biopsy in half of the patients who were initially tested negative for *T790M* mutation in their plasma. Second, the yield of acquired *T790M* mutation from different sites of tissue biopsied was not the same. Third, even though PR with *EGFR*-TKI treatment was a predictor for acquiring *T790M* mutation, this resistance mutation was detected in two-fifths of patients with SD as the best tumor response.

The strength of this study lies in the fact that only patients who were treated with first- or second-generation *EGFR*-TKI were included, therefore excluding the potential tumorigenic effect of chemotherapy. In addition, this study concurrently explores the association of acquired *T790M* mutation with patient baseline demographics and clinical characteristics, treatment history, pattern of disease progression and investigation methods.

However, we do acknowledge that the study has several limitations. First, it was performed in a single centre, thus limiting the generalizability of the results. Second, this was a retrospective study with attendant limitations. Third, patients who experienced PD within six months of initial *EGFR*-TKI treatment or had interrupted *EGFR*-TKI treatment were excluded. Such patients were not uncommon in real-life practice. Fourth, patients with rare or complex *EGFR* mutation were not included because none of them had objective clinical benefit from initial *EGFR*-TKI treatment. Fifth, the acquired *T790M* mutation in patients who develop new symptomatic brain metastases on PD might have been underreported because brain biopsy was rarely performed. Sixth, the post-progression survival and overall survival of these patients were not assessed because of the heterogeneity or absence of subsequent lines of treatment.

Conclusions {#S0005}
===========

This study concludes that acquired *T790M* mutation is the most common resistance mechanism leading to first- or second-generation *EGFR*-TKI treatment failure in Malaysian patients. The best tumor response of PR was an independent predictor of *T790M* mutation as a resistance mechanism. Patients with tumour harboring *exon 19* deletion mutation as the original sensitizing mutation are more likely to acquire *T790M* mutation causing PD. These information are useful for clinicians to prognosticate and plan subsequent treatments for patients with advanced NSCLC harbouring *EGFR* mutations.
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